Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Dyslipidemia with hypertesion~* msSBP \< 180 mmHg~* msDBP \< 110 mmHg~* LDL-C ≤ 250 mg/dL~* Triglycerides \< 400 mg/dL~Exclusion Criteria:~* At Visit 3, BP difference SBP ≥20mmHg or DBP ≥10mmHg~* CK normal range ≥ 2 times~* Uncontrolled primary hypothyroidism(TSH normal range ≥ 1.5 times)~* AST or ALT ≥ 2 times~* Uncontrolled diabetes mellitus (HbA1c≥9%)~* CLcr \< 30 mL/min/1.73m\^2~* K \> 5.5 mEq/L~* Other exclusion applied

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I (Type: EXPERIMENTAL): Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin 20 mg for 8 weeks
- Group II (Type: ACTIVE_COMPARATOR): Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo for 8 weeks
- Group III (Type: ACTIVE_COMPARATOR): Treatment of Telmisartan 80 mg, Amodipine placebo, Rosuvastatin 20 mg for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).